Skip to content

Nephrodite’s Holly™ Implantable Continuous Dialysis System Selected for FDA TAP Program

Nephrodite, Inc. announced that its Holly™ Implantable Continuous Dialysis System has been selected to participate in the FDA’s TAP program, aimed at accelerating the development and patient access of innovative medical technologies for end-stage kidney disease.

ATLANTA–(BUSINESS WIRE)–Nephrodite, Inc., a medical device company developing an implantable, continuous renal replacement system, today announced that its Holly™ system has been selected to participate in TAP by the U.S. Food and Drug Administration (FDA). “We are dedicated to moving our technology as quickly and safely as possible into healthcare systems for eligible patients with end-stage kidney disease to stop the burden of three-times-weekly, clinic-based dialysis and improve their phys